Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors

類似資料

• Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer
  著者:: Doi, Toshihiko, 等
  出版事項: (2013)
• A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors
  著者:: Doi, Toshihiko, 等
  出版事項: (2016)
• Effect of food on the pharmacokinetics of TAS‐102 and its efficacy and safety in patients with advanced solid tumors
  著者:: Yoshino, Takayuki, 等
  出版事項: (2016)
• Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors
  著者:: Doi, Toshihiko, 等
  出版事項: (2012)
• A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer
  著者:: Kawazoe, Akihito, 等
  出版事項: (2015)